OCGN Aug 2022 1.500 call
| Previous Close | 0.7500 |
| Open | 0.8000 |
| Bid | 0.8300 |
| Ask | 3.3500 |
| Strike | 1.50 |
| Expire Date | 2022-08-05 |
| Day's Range | 0.7500 - 1.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
- Motley Fool
Ocugen, Inc. (OCGN) Q2 2022 Earnings Call Transcript
Joining me today are Ocugen's chairman and CEO and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide more on our financial results. Earlier this morning, we issued a press release detailing business activity for Q2 2022.
- GlobeNewswire
Ocugen Provides Business Update & Second Quarter 2022 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET Dosing patients in U.S. Phase 2/3 COVAXIN™ (BBV152) clinical trialCompleted dosing of patients in Cohort 1 of OCU400 gene therapy product candidateExpanding product pipeline with the regenerative medicine cell therapy program NeoCart® MALVERN, Pa., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and
- Zacks
Ocugen Q2 Preview: Rebound Quarter Inbound?
Ocugen shares have struggled over the last year, declining more than 60% in value and vastly underperforming the S&P 500.
